Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

STATUS

Recruiting
End date

Aug 26, 2027
participants needed

500
sponsor

Novartis Pharmaceuticals

Send

Updated on 19 February 2024

See if I qualify

stem cell transplantation

cell transplantation

azacitidine

leukemia

chronic myelomonocytic leukemia

myelomonocytic leukemia

cmml-2

high risk myelodysplastic syndrome

myelodysplastic syndrome

Summary

This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line setting and are not eligible for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) according to medical judgment by the investigator.

Details

Condition	Chronic myelomonocytic leukemia, Preleukemia, MYELODYSPLASTIC SYNDROME
Age	18-100 years
Treatment	Placebo, Azacitidine, MBG453
Clinical Study Identifier	NCT04266301
Sponsor	Novartis Pharmaceuticals
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Signed informed consent must be obtained prior to participation in the study
	Age 18 years at the date of signing the informed consent form
	Morphologically confirmed diagnosis of myelodysplastic syndrome (MDS) based on WHO 2016 classification (Arber et al 2016) by local investigator assessment with one of the following Prognostic Risk Categories, based on the revised International Prognostic Scoring System (IPSS-R)
	Very high (> 6 points)
	High (> 4.5 - 6 points)
	Intermediate (> 3 - 4.5 points) Or Morphologically confirmed diagnosis of Chronic Myelomonocytic Leukemia -2 based on WHO 2016 classification (Arber et al 2016) by local investigator assessment with WBC < 13 x 109/L
	Indication for azacitidine treatment according to the investigator, based on local standard medical practice and institutional guidelines for treatment decisions
	Not eligible for intensive chemotherapy according to the investigator, based on local standard medical practice and institutional guidelines for treatment decisions
	Not eligible for hematopoietic stem cell transplantation according to the investigator, based on local standard medical practice and institutional guidelines for treatment decisions
	Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Exclusion Criteria
	Prior exposure to TIM-3 directed therapy at any time. Prior therapy with immune checkpoint inhibitors (e.g, anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2), cancer vaccines is allowed except if the drug was administered within 4 months prior to randomization
	Previous first-line treatment for intermediate, high, very high risk myelodysplastic syndromes (based on IPSS-R) or CMML with any antineoplastic agents including for example chemotherapy, lenalidomide and hypomethylating agents (HMAs) such as decitibine and azacitidine. However, previous treatment with hydroxyurea or leukopheresis to reduce WBC count is allowed prior to randomization
	Investigational treatment received within 4 weeks prior to randomization. In case of a checkpoint inhibitor: a minimal interval of 4 months prior to randomization is necessary to allow randomization
	Subjects with Myelodysplastic syndrome (MDS) based on 2016 WHO classification (Arber et al 2016) with revised International Prognostic Scoring System (IPSS-R) 3
	Diagnosis of acute myeloid leukemia (AML) including acute promyelocytic leukemia and extra-medullary acute myeloid leukemia, primary or secondary myelofibrosis based on WHO 2016 classification (Arber et al 2016)
	Diagnosis of therapy related myeloid neoplasms based on WHO 2016 classification (Arber et al 2016)
	History of organ or allogeneic hematopoietic stem cell transplant
	Other protocol-defined Inclusion/Exclusion Criteria may apply

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

stem cell transplantation

cell transplantation

azacitidine

leukemia

chronic myelomonocytic leukemia

myelomonocytic leukemia

cmml-2

high risk myelodysplastic syndrome

myelodysplastic syndrome

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)